Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 692 results for "nexium"

Cipla rises 2%, Credit Suisse upgrades on firm Nexium sales

According to the brokerage, Nexium profits leading to strong earnings growth in H1FY16 and approval of generic Advair MDI in UK are strong near-term triggers of Cipla. Money Control, 1 week ago

11 images for nexium

NPR, 3 weeks ago
BusinessInsider.co.id, 3 weeks ago
KNAU, 3 weeks ago
Bloomberg, 3 weeks ago
Yahoo!Xtra, 3 weeks ago
Kaiser Health News, 3 weeks ago
9ija News.com, 3 weeks ago
NewsReality.com, 3 weeks ago
CNBC, 3 weeks ago
4 Traders, 3 weeks ago
CNBC

AstraZeneca eyes new cancer deals after Nexium hit

AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market. The drugmaker, which ...
 CNBC1 month ago UPDATE 1-AstraZeneca looks beyond Nexium hit with new cancer deals  CNBC1 month ago UPDATE 2-AstraZeneca looks beyond Nexium hit with new cancer deals  Reuters UK1 month ago REUTERS - UPDATE 2-AstraZeneca looks beyond Nexium hit with new cancer deals  Namibia Press Agency1 month ago
[x]  

Nexium Boost for Cipla; raises target to Rs 626: Nomura

Nomura Financial Advisory and Securities expects Cipla to gain significantly from gNExium in the near term, which should help company counter the adverse impact of currency movements and slippage in EU inhaler pick up, in our view. ''Based on Teva's ...
 MyIris2 weeks ago Nomura downgrades Lupin to Neutral  MyIris1 month ago Lupin plunges 5%, Nomura downgrades to neutral, cuts target  Moneycontrol.com1 month ago

Nexium Costliest Drug Prescribed in Medicare Part D, CMS Data Show

AstraZeneca's acid-reflux drug Nexium was the highest-costing drug prescribed under Medicare Part D in 2013, totaling $2.5 billion, according to new data released by the Centers for Medicare & Medicaid Services. Of the top five drugs by cost, ...
 FDA News2 weeks ago AstraZeneca plc (ADR) (AZN) Nexium Most Prescribed Drug Under Medicare Part D Program  Bidness Etc3 weeks ago AstraZeneca plc Has a Rocky First-Quarter: Here's What You Need to Know  Motley Fool1 month ago AstraZeneca plc (ADR) (AZN) Q1 Profits Decline Amid Patent Expiry Of Top Drugs  Bidness Etc1 month ago
[x]  

Why Medicare's List Of Costly Drugs Is Kind Of Bogus

No, the most expensive drug for the U.S. Medicare drug benefit program is not Nexium, the heartburn medicine no matter what Medicare says. According to data released by the Centers for Medicare & Medicaid Services last night and put in a ...
 Forbes.com3 weeks ago
NPR

Nexium, Advair led Medicare drug spending in 2013 - officials

The Centers for Medicare and Medicaid Services (CMS (HKSE: 0867-OL.HK - news) ) said AstraZeneca Plc (NYSE: AZN - news) 's Nexium for acid reflux topped the list with prescriptions totaling $2.5 billion, followed by $2.3 billion of GlaxoSmithKline ...
 Yahoo! UK and Ireland3 weeks ago Brand-Name Medicines Dominate Medicare's $103 Billion Drug Bill  NPR3 weeks ago CMS Report: Nexium, Advair Led Medicare Drug Spending in 2013  Pharmscope3 weeks ago UPDATE 1-Nexium, Advair led Medicare drug spending in 2013 -officials  Reuters UK3 weeks ago
[x]  

Expect FY16 US generic launch for Nexium: Lupin

In an interview with CNBC-TV18, CFO S Ramesh spoke to Latha Venkatesh and Sonia Shenoy about a recent acquisition and other developments such as a recent FDA audit at its Indore facility as well as its plans to launch a generic version of the world’s ...
 Money Control2 months ago
Pharmaceutical Manufacturing Magazine

Ranbaxy fails to reverse FDA decision over Valcyte and Nexium

Indian generics company Ranbaxy has yet again failed in its bid to become the first company in the US to sell generic versions of the AstraZeneca blockbuster acid-reflux drug Nexium (esomeprazole) and F. Hoffman-La Roche's cytomegalovirus treatment ...
 GaBi Online2 months ago Judge Rules in Favor of FDA in Ranbaxy Drug Approval Suit  Pharmaceutical Manufacturing Magazine2 months ago Ranbaxy loses approvals, exclusivity of 2 drugs in US  DNA2 months ago UPDATED: Sun winds up Ranbaxy deal  FiercePharma1 month ago
[x]  
Reuters

US judge denies Ranbaxy to launch Valcyte, Nexium copy

Launching the first generic copies of the drugs would have given Ranbaxy six months of exclusivity on the market. FDA had said its earlier decision granting the approvals was "in error" as Ranbaxy's plants at the time were not compliant with the US ...
 Economic Times2 months ago U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies  Reuters2 months ago US judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies  Business Standard2 months ago
Yahoo! News Australia

AstraZeneca posts drop in first-quarter sales, profit on generic competition to Nexium, Crestor

AstraZeneca reported Friday that first-quarter core profit slipped 7 percent year-over-year to $1.4 billion, as the company's results were hit by generic competition to Nexium and Crestor. Revenue in the three-month period declined 6 percent to $6.1 ...
 FirstWord Pharma1 month ago AstraZeneca hit by copycat Nexium and strong dollar in Q1  London South East1 month ago AstraZeneca sales retreat in its effort to achieve huge growth by 2023  FiercePharma1 month ago AstraZeneca announces new cancer deals with first-quarter results  ExecReview.com1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - nexium
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less